Trumps Tariff Policy Pressures Healthcare Stocks

Key Highlights

• Trump’s tariff escalation:
• • A full 100% duty will be imposed on branded and patented pharmaceutical imports starting October 1.
  • A 50% levy has been announced on imports of kitchen cabinets and bathroom vanities.
  • 30% tariff on upholstered furniture.
  • 25% tariff on heavy trucks.
  • Pledged to push US interest rates down to 2%.

• ASX session recap:
• The benchmark index ended flat, as weakness in healthcare was balanced by strength in mining and financials.
• Sector performance:
  • Healthcare: The biggest drag, pressured by the pharmaceutical tariff announcement.
  • Resources: Strong gains across lithium and uranium.
  • Banks: Positive bias, adding modest support to the broader index.

Macro & Policy

• United States:

The sudden tariff moves poses significant risks to global supply chains and raises fresh concerns about inflationary pressures. Pharmaceutical imports face the most disruption, as future access hinges on US-based manufacturing commitments. The push for a rapid rate cut to 2% adds policy uncertainty, with investors weighing growth support against inflation risks.

• Australia:

Markets broadly anticipate that the Reserve Bank will keep the cash rate steady at 3.60% in its next policy decision. Inflation ticked up to 3.0% year-on-year in August, 2025 keeping policymakers cautious. Economists remain divided on when rate cuts will materialize, though most anticipate easing toward the end of 2025.

Outlook

Investors should expect elevated volatility in healthcare as tariff policy uncertainty persists. Companies with diversified manufacturing or domestic US production will be relatively better positioned.

The rally in miners and energy-related stocks highlights ongoing sector rotation toward commodities with stronger demand tailwinds.

Conclusion

Trump’s tariff escalation has shifted investor focus sharply toward supply chain resilience, with healthcare names bearing the brunt of the selloff. Miners and energy explorers provided crucial support, keeping the ASX flat overall.

Near-term, markets will closely watch whether tariffs stick beyond October and how central banks’ balance trade-driven inflation risks with growth concerns. Investors should maintain selective exposure, favoring resource names with momentum, while exercising caution in healthcare until greater clarity emerges.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au